GLP-1 receptor agonists
Semaglutide (Ozempic, Wegovy, Rybelsus), tirzepatide (Mounjaro, Zepbound), liraglutide (Victoza, Saxenda). The most-denied drug class in US insurance — and one of the most commonly reversed on appeal.
What this class is
GLP-1 receptor agonists are a drug class that mimics the action of glucagon-like peptide-1 to improve glycemic control, reduce body weight, and (for some agents) reduce cardiovascular events. Originally FDA-approved for type 2 diabetes, several agents now have separate FDA approvals for chronic weight management and cardiovascular risk reduction. The class drove a generational shift in obesity, diabetes, and cardiovascular care.
Representative drugs
- Semaglutide (Ozempic, Wegovy, Rybelsus)
- Tirzepatide (Mounjaro, Zepbound)
- Liraglutide (Victoza, Saxenda)
- Dulaglutide (Trulicity)
- Exenatide (Byetta, Bydureon)
Common denial patterns
- Weight-loss exclusion (CARC 204) — plan excludes weight-loss drugs as a benefit category
- Step therapy requiring oral semaglutide before injectable
- Step therapy requiring older diabetes meds before GLP-1
- BMI threshold (plan requires BMI ≥30 or 35 vs FDA label ≥27)
- Non-formulary with no alternative in class
- Quantity limit on monthly dose
Clinical guidelines that win appeals
- 2021 AHA/ACC/TOS Guideline on Evaluation and Management of Obesity — pharmacotherapy as standard of care
- ADA Standards of Care 2024 — GLP-1 agonists with cardiovascular benefit at Level A
- Endocrine Society Clinical Practice Guideline 2015 — pharmacotherapy for obesity BMI ≥30 or ≥27+comorbidity
- SELECT trial 2023 — semaglutide 2.4mg cardiovascular outcomes
Frequently asked questions
What is glp-1 receptor agonists?
GLP-1 receptor agonists are a drug class that mimics the action of glucagon-like peptide-1 to improve glycemic control, reduce body weight, and (for some agents) reduce cardiovascular events. Originally FDA-approved for type 2 diabetes, several agents now have separate FDA approvals for chronic weight management and cardiovascular risk reduction. The class drove a generational shift in obesity, diabetes, and cardiovascular care.
What are the common denial patterns?
Weight-loss exclusion (CARC 204) — plan excludes weight-loss drugs as a benefit category; Step therapy requiring oral semaglutide before injectable; Step therapy requiring older diabetes meds before GLP-1; BMI threshold (plan requires BMI ≥30 or 35 vs FDA label ≥27); Non-formulary with no alternative in class; Quantity limit on monthly dose.
Which clinical guidelines support appeals?
2021 AHA/ACC/TOS Guideline on Evaluation and Management of Obesity — pharmacotherapy as standard of care; ADA Standards of Care 2024 — GLP-1 agonists with cardiovascular benefit at Level A; Endocrine Society Clinical Practice Guideline 2015 — pharmacotherapy for obesity BMI ≥30 or ≥27+comorbidity; SELECT trial 2023 — semaglutide 2.4mg cardiovascular outcomes.
Related
- GLP-1 weight-loss drugsWegovy, Zepbound, Mounjaro, Ozempic, Saxenda
- Diabetes drugs & insulinInsulin analogs, GLP-1 for T2D, SGLT2, DPP-4, Afrezza, pump supplies, glucagon rescue
- Bariatric surgery — RYGB, sleeve, duodenal switch, SADI-S, revision, ESGRoux-en-Y gastric bypass, sleeve gastrectomy, BPD/DS, SADI-S, revision bariatric surgery, endoscopic sleeve gastroplasty
- Antifibrotic agentsPirfenidone (Esbriet), nintedanib (Ofev) for idiopathic pulmonary fibrosis (IPF) and progressive pul
- Biologic drugs (mAbs and biosimilars)Monoclonal antibodies and other biologics targeting specific immune or growth pathways. Used in rheu
- BiosimilarsFDA-approved highly-similar versions of reference biologics. Plans frequently require biosimilar use
- Direct oral anticoagulants (DOACs)Apixaban (Eliquis), rivaroxaban (Xarelto), dabigatran (Pradaxa), edoxaban (Savaysa). Replaced warfar
Sources
Appeal a glp-1 receptor agonists denial
Upload your denial — DenialHelp drafts a physician-ready appeal letter in five minutes with the right clinical guideline and federal regulation cited. $39 first-level, money back if we can't draft a strong appeal.
Get started →Contact: hello@denialhelp.com